Citigroup analyst Patrick Donnelly downgrades Syneos Health (NASDAQ:SYNH) from Buy to Neutral and lowers the price target from $115 to $105.
November 12, 10:27 AM
Laboratory Corp of America Holdings (NYSE:LH) is in talks to combine some of its assets with Syneos Health Inc (NASDAQ:SYNH), reports Bloomberg citing…
November 5, 7:17 AM
Barclays analyst Luke Sergott upgrades Syneos Health (NASDAQ:SYNH) from Equal-Weight to Overweight and raises the price target from $98 to $115.
November 3, 12:06 PM
According to Benzinga Pro, during Q3, Syneos Health (NASDAQ:SYNH) earned $113.36 million, a 35.46% increase from the preceding quarter. Syneos Health also posted a total of $1.35 billion in sales, a 5.12% increase since Q2.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2:23 PM
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 7:46 AM
Here's a roundup of top developments in the biotech space over the last 24 hours.
September 20, 12:31 PM
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT September Update